SEATTLE--(BUSINESS WIRE)--Blaze Bioscience, Inc., a biotechnology company focused on guided cancer therapy, announced today that the company has received clearance from the United States Food and Drug Administration (FDA) for the first Phase 1 clinical study under their Tumor Paint BLZ-100 Investigational New Drug application (IND). The Phase 1b study entitled “A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects with Glioma Undergoing Surgery” will enroll up to twenty-one (21) patients and is being conducted at sites in the U.S. and Australia.
Help employers find you! Check out all the jobs and post your resume.
